learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Search
forLearn
5 / 801 resultslearn GHK-Cu Copper Tripeptide
learn 18β-glycyrrhetinic acid
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Tricopper peptides
Research
5 / 1000+ results
research Pathogenic Mechanisms and Mechanism‐Directed Therapies for Androgenetic Alopecia: Current Understanding and Future Directions
Targeting multiple pathways may improve treatments for androgenetic alopecia.
research Wnt/β-Catenin Signaling Pathway Targeting Androgenetic Alopecia: How Far Can We Go Beyond Minoxidil and Finasteride?
Targeting the Wnt/β-catenin pathway may lead to better treatments for hair loss.
research Signal integrator function of CXXC5 in Cancer
CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
research In Vitro and In Vivo Models for the Development of Hair Growth Materials By Regulating the β-Catenin Signaling Pathways
The research found a way to develop hair growth materials by targeting a specific signaling pathway.
research KY19382, a novel activator of Wnt/β‐catenin signalling, promotes hair regrowth and hair follicle neogenesis
KY19382 helps regrow hair and create new hair follicles.
Community Join
5 / 1000+ resultscommunity Korean scientists breakthrough in hair regeneration targeting CXXC5 protein and WNT Signaling Pathway
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community Anyone here ever used KY-19382 or another indirubin analogue?
KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.